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Abstract
Background Surgical risk scores are used to identify high-
risk patients for surgical mitral valve repair. There is no
scoring system to estimate the mortality risk for patients
undergoing percutaneous treatment. The aim of this analy-
sis is to evaluate the predictive value of the EuroSCOREs
and the Society of Thoracic Surgeons Predicted Risk of
Mortality Score (STS) for periprocedural mortality in per-
cutaneous edge-to-edge mitral valve repair.
Methods From 2009 to 2013, 136 high-risk patients
were included who underwent 143 procedures. Observed
periprocedural mortality was compared with predicted
mortality using the logistic EuroSCORE, EuroSCORE II
and STS. The predictive value was analysed by receiver
operating characteristic curves for each score.
Results Observed periprocedural mortality was 3.5 %. The
predicted surgical mortality risk was: 23.1 ± 15.7 % for the
logistic EuroSCORE, 9.6 ± 7.7 % for the EuroSCORE II
and 13.2 ± 8.2 % for the STS. The predictive value esti-
mated by the area under the curve was: 0.55, 0.54 and 0.65
for the logistic EuroSCORE, EuroSCORE II and STS re-
spectively. Severe pulmonary hypertension and acute pro-
cedural success were significant predictive parameters in
univariate analysis.
Conclusion Contemporary surgical scores do not ad-
equately predict periprocedural mortality for high-risk
patients undergoing edge-to-edge mitral valve repair, but
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they can be used to help decision-making in the selection
process for this procedure.
Keywords Mitral valve repair · Percutaneous ·
EuroSCORE · STS
Background
Mitral regurgitation (MR) is the second most prevalent
valve disease after aortic stenosis [1]. If untreated, se-
vere MR can lead to progressive heart failure and reduced
survival [2]. Currently, the standard for MR treatment is
surgical mitral valve (MV) repair [3]. However, for many
patients with severe MR, the surgical risk is considered too
high. In these patients, percutaneous treatment of MR is an
alternative therapy [4]. The best-established technique to
date is the transcatheter edge-to-edge MV repair with the
MitraClip® system (Abbott Vascular Inc. Santa Clara, CA,
USA), which creates a double orifice, mimicking the sur-
gical edge-to-edge technique introduced by Ottavio Alfieri
[5]. The first in-human implantation was performed in June
2003 [6]. Since then, several studies have proven the safety
and efficacy of this percutaneous treatment [7–14]. High-
risk surgical or inoperable patients are potential candidates
for this procedure. In current practice, the technique is
predominantly used in the presence of functional MR [13].
To identify high-risk or inoperable patients who might
be eligible for percutaneous MV repair, different well-es-
tablished surgical risk models can be used to estimate oper-
ative mortality. The EuroSCOREs and the Society of Tho-
racic Surgeons Predicted Risk of Mortality Score (STS) are
mostly used [4]. The logistic EuroSCORE was published in
1999 and is based on an international European database in-
cluding patients predominantly undergoing coronary artery
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Tab. 1 Pre-procedural patient characteristics
n = 136
Patient-related factors
Age, years 74.5 ± 9.4
Male 92 (67.6)
BMI, kg/m2 25.9 ± 4.7
Comorbidities
Diabetes mellitus 31 (22.8)
Hypertension 70 (51.5)
Atrial fibrillation 72 (52.9)
COPD 28 (20.6)
Renal failurea 54 (39.7)
Previous myocardial infarction 69 (50.7)
Previous CABG 58 (42.6)
Previous MV repair 2 (1.5)
Stroke/TIA 20 (14.7)
Performance
NYHA III or IV 122 (89.7)
Quality of life index score 50 ± 23
6-MWT distance, m 273 ± 120
Laboratory findings
NT proBNP, pg/ml 4591 ± 6178
Haemoglobin, mmol/l 7.9 ± 1.0










Resynchronisation therapy 30 (22.1)
Values are mean ± SD or n (%)
BMI body mass index, CABG coronary artery bypass graft,
COPD chronic obstructive pulmonary disease, CRT cardiac
resynchronisation therapy, LVEF left ventricle ejection fraction,
MR mitral regurgitation, NYHA New York Heart Association,
TIA transient ischaemic attack, 6-MWT 6-minute walk test
aGlomerular filtration rate < 45 ml/min/1.73 m2
bAccording to the two classes in the EuroSCORE II: moderate
pulmonary hypertension is a systolic pulmonary artery pressure
(sPAP) between 31–55 mmHg, severe pulmonary hypertension is
a sPAP above 55 mmHg
bypass graft surgery [15, 16]. A revised version, the Eu-
roSCORE II, was developed in 2011 [17]. For surgically
treated patients, Noyez et al. have proven the latter to be
a more accurate version with a reduction of predicted risk
of about 50 % [18]. The STS dates from January 2008 and
includes a model specifically applicable for MV repair [19].
All of the three scoring models define perioperative mor-
tality as in-hospital or 30-day mortality. As these models
aim to predict mortality in cardiac surgery, they may not
be applicable for percutaneous MV repair. Despite the fact
that the percutaneous procedure is considered to be a safer
alternative for mitral surgery, it can still be accountable for
potentially life-threatening complications [20]. Reliable es-
timation of the mortality risk would contribute to adequate
patient selection for this procedure. The aim of this ret-
rospective observational study is to examine the predictive
value of the EuroSCOREs and the STS for periprocedural




From January 2009 to April 2013, 143 percutaneous MV
procedures were performed in 136 consecutive patients at
our institution. The Heart Team referred patients for percu-
taneous MV repair after careful deliberation. All patients
suffered from moderate-to-severe (3+) or severe (4) MR,
according to the recommendations of the American Soci-
ety of Echocardiography [21], and were considered high
risk for conventional surgery (logistic EuroSCORE > 20 %
or the presence of specific risk factors for morbidity or
mortality decided by the Heart Team). Baseline characteris-
tics, including medical history, laboratory findings and New
York Heart Association (NYHA) classification, were col-
lected and entered into a web-based electronic registry. The
local institutional review board approved the study protocol
(R&D/Z-13.15/MitraClip).
Risk scores
The logistic EuroSCORE, EuroSCORE II and STS were
calculated using online calculators (http://riskcalc.sts.org
and http://www.euroscore.org, respectively). The two Eu-
roSCOREs are subdivided into three categories (patient
related, cardiac related and operation related), and com-
prise 17 and 18 variables for the logistic EuroSCORE
and EuroSCORE II, respectively. The STS is divided
into 8 categories (procedure, demographics, risk factors,
previous interventions, preoperative cardiac status, preop-
erative medications, haemodynamics and catheterisation,
and valve pathology) and consists of 41 variables. In the
STS, MV repair was specifically indicated. Frequently used
cut-off values to define high surgical risk for the logistic
EuroSCORE (≥20) and the STS (≥12) were applied [12,
13]. For the EuroSCORE II no commonly used limit is
available, therefore data were arbitrarily analysed for the
threshold values of ≥5 and ≥10 %.
Neth Heart J (2016) 24:475–480 477
Fig. 1 ROC curve analysis for the prediction of periprocedural mor-
tality. Green line LES: 55.1 %, red line ES II: 53.6 %, blue line STS:
65.1 %
Procedural technique
Percutaneous MV repair was performed by means of the
MitraClip® system, as previously described [9].
Endpoints definition
The main endpoint of this analysis was periprocedural
mortality, defined as 30-day mortality or in-hospital death
after the procedure, similar to the definition used in the risk
scores.
Statistical analysis
Descriptive statistics were used to report patient charac-
teristics. Continuous variables were reported as mean ±
standard deviation. Frequencies and percentages were used
to report nominal variables. The prognostic value of the
EuroSCOREs and the STS was evaluated in terms of dis-
crimination, assessed by a receiver operating characteristic
(ROC) analysis, producing an area under the curve (AUC)
with probability values (p-value). A two-sided p-value of
< 0.05 was considered significant. Furthermore, the mortal-
ity ratio was calculated by dividing the observed mortality
by the predicted mortality multiplied by 100. This was done
for the different cut-off values. If this ratio equals 100 %,
then the number of observed deaths equals that of predicted
cases. To identify other risk factors, patient characteristics
of the periprocedural mortality group were compared with
survivors using the Fisher’s exact test for nominal variables
and the independent Student’s t-test for continuous vari-
ables. All statistical analyses were performed using SPSS
software (SPSS version 21.0 for Windows, IBM, Armonk,
New York) and R (version 2.15, www.r-project.org).
Results
A total of 143 percutaneous MV procedures were per-
formed in 136 patients (mean age: 74.5 ± 9.4 years, male:
67.6 %, Tab. 1). Acute procedural success, defined as a re-
duction of the MR to grade  2+, was achieved in 132 of
143 procedures (92.3 %) [14]. Due to a failed index proce-
dure or recurrent MR, 7 patients underwent a “redo” proce-
dure. Furthermore, in 5 patients no clip was implanted for
different reasons: either no reduction of the MR could be
achieved after grasping the leaflets (n = 2) or the patient’s
anatomy proved unsuitable for MitraClip ® treatment (n =
2). One patient died before clip placement during an ur-
gent redo procedure due to worsening MR after myocar-
dial infarction. All procedures, including failed procedures
and redo procedures, were reported and analysed, thus ex-
amining the periprocedural mortality for every procedure.
Within 30 days, 5 deaths had occurred. None of the patients
who were alive at 30 days died before hospital discharge,
resulting in a periprocedural mortality rate of 3.5 %. The
cause of death was cardiovascular in all cases; 4 patients
died due to end-stage heart failure and 1 patient died due
to a sudden cardiac arrest without preceding symptoms of
heart failure.
EuroSCOREs and STS score analysis
The overall 30-day or in-hospital risk of mortality estimated
by the logistic EuroSCORE, EuroSCORE II and STS was
23.1 ± 15.7 %, 9.6 ± 7.7 % and 13.2 ± 8.2 %, respectively
(Tab. 2). Since the observed mortality was 3.5 %, all scores
overestimated the risk of mortality.
The discriminating value of the three scores was ex-
amined in an ROC curve analysis for the prediction of
periprocedural mortality (area under the curve: 0.55 (p =
0.69) for the logistic EuroSCORE vs 0.54 (p = 0.78) for
the EuroSCORE II vs 0.65 (p = 0.25) for the STS, Tab. 2
and Fig. 1). Although the STS outperformed both Eu-
roSCORES, none of the scores showed a significant cor-
relation with periprocedural mortality.
When applying different cut-off values for the identifi-
cation of very high-risk patients, the association between
the observed and predicted mortality was poor. The Eu-
roSCORE II with a cut-off value of ≥5 % showed the high-
est mortality ratio of 32.6 (Tab. 3).
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Tab. 2 The prognostic value of the logistic EuroSCORE, EuroSCORE II and the STS score
Predicted mortality AUC (95 % CI) p-value
LES 23.1 ± 15.7 0.55 (0.32–0.78) 0.70
ES II 9.6 ± 7.7 0.54 (0.30–0.77) 0.78
STS 13.2 ± 8.2 0.65 (0.49–0.81) 0.25
Values are mean ± SD
LES Logistic EuroSCORE, ESII EuroSCORE II, STS Society of Thoracic Surgeons Predicted Risk of Mortality Score, AUC area under the curve,
CI confidence interval
Tab. 3 The observed to predicted mortality for different cut-off values for peri-procedural mortality
Cut-off value % of procedures Observed Mortality Predicted Ratio
LES ≥ 20 49.6 4.2 (0.9–11.9) 35.1 12.0
ES II ≥ 5 67.1 4.2 (1.1–10.3) 12.9 32.6
ES II ≥ 10 39.7 3.7 (0.5–12.7) 17.5 21.1
STS ≥ 12 47.5 5.9 (1.6–14.2) 20.0 29.5
Values are % (95 % confidence interval)
LES Logistic EuroSCORE, ESII EuroSCORE II, STS Society of Thoracic Surgeons Predicted Risk of Mortality Score
The predictive value of each baseline characteristic was
assessed in univariate analysis. Severe pulmonary hyperten-
sion was identified as a predictor for perioperative mortality
(OR 7.5; CI 95 % 1.2–47.4, p = 0.04). Furthermore, pa-
tients with acute procedural success showed significantly
lower perioperative mortality (OR 0.1; 95 % CI 0.02–0.7,
p = 0.05). NYHA functional class also seemed to predict
periprocedural mortality due to statistical significance, but
it has less predictive value due to an odds ratio near 1 (OR
1.08, 95 % CI 1.00–1.16, p = 0.04).
Discussion
The aim of this observational study was to examine the
predictive value for periprocedural mortality of the conven-
tional surgical risk scores in high-risk patients undergoing
percutaneous MV repair.
The observed periprocedural mortality was 3.5 % in
143 procedures. Our results show a distinct overestima-
tion of the mortality risk by all three risk models. Also,
when cut-off values were applied, the mortality ratio was
nowhere near 100 %, which confirms that the scores are not
accurate in predicting periprocedural mortality in percuta-
neous MV repair. These findings are unsurprising, since
the surgical risk scores were designed to predict mortality
in patients undergoing open-heart surgery instead of percu-
taneous procedures. Hence, it is not only expected, but also
required that the scores overestimate the actual periprocedu-
ral mortality risk. However, an earlier analysis by our group
showed that patients with high-surgical risk (mean logistic
EuroSCORE of 33.8 ± 9.0 %) who are denied surgical treat-
ment can be successfully treated by using percutaneous MV
repair leading to a 30-day mortality of 0 % [22]. The same
is true for a study by Pleger et al. [8], with a mean logistic
EuroSCORE of 41 ± 7 % and 30-day mortality of 0 %.
Thus, the risk scores can be useful in identifying high-risk
surgical patients in order to select them for percutaneous
MV treatment as a safer alternative for surgery.
Furthermore, the two EuroSCOREs and the STS score
date from 1999, 2011 and 2008 respectively [15–17, 19].
With surgical techniques and postoperative care improving,
the scores are apt to overestimate the risk of perioperative
mortality [23].
Previous studies show similar results: the large
ACCESS-EU registry showed a periprocedural mortality
rate of 3.4 % with a mean logistic EuroSCORE of 23.0 ±
18.3 % and the TRAMI registry showed a periprocedural
mortality of 2.5 % with a median logistic EuroSCORE
of 23.0 % (interquartile range of 12–38 %) and a me-
dian STS of 11.0 % (interquartile range of 4–19 %) [11,
13]. Recently, a publication from the GRASP-IT registry
also stated that all three scores overestimated mortality at
30 days with an observed mortality rate of 3.3 % (mean of
17 ± 5 %, 7 ± 8 % and 8 ± 7 % for logistic EuroSCORE,
EuroSCORE II and STS respectively). All scores could
distinguish between low- and high-risk groups at 3-year fol-
low-up, the EuroSCORE II and logistic EuroSCORE also
being able to discriminate at a 30-day term. However, none
of the scores were correctly calibrated for periprocedural
mortality rate [24].
These studies, in agreement with our analysis, prove that
the surgical risk scores overestimate the 30-day observed
mortality rate in percutaneous MV repair.
Even though percutaneous MV repair proves to be rel-
atively safe, life-threatening complications can occur [20].
A dedicated risk model for the percutaneous MV proce-
dure might facilitate patient selection. In this observational
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study, only severe pulmonary hypertension could be iden-
tified as a significant and relevant pre-procedural predictor
for periprocedural mortality in univariate analysis. This
outcome made development of a mortality prediction tool
for percutaneous MV repair unattainable and beyond the
scope of this analysis. Several other studies have identified
variables to be predictors for mortality such as: elevated
NT-proBNP, chronic obstructive pulmonary disease, kidney
failure, previous valve surgery, tricuspid valve insufficiency,
NYHA IV and pre-procedural MR grade [25–29]. However,
so far there remains little consistency and studies have been
conducted with too few patients to mimic the realisation of
a model such as the EuroSCORE [15, 30]. A well-designed
study with a larger dataset and more events could be able
to develop such a risk score for percutaneous MV repair.
Limitations
The data were gathered from a single centre, which might
induce selection bias by the heart team process. Addition-
ally, since the observed periprocedural mortality was low
(3.5 %), a larger sample size could have led to more reliable
results.
Conclusion
The results of this analysis show that conventional risk
scores overestimate the periprocedural mortality in patients
undergoing percutaneous MV repair. However, the risk
scores are useful in identifying eligible patients for percu-
taneous treatment. A dedicated risk model for estimation
of the mortality risk for percutaneous MV repair could op-
timise patient selection for this procedure.
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